Pharma Industry

Experts examine drug pricing policies and potential effects of new tariffs on imports.

Medical groups warn of eroding trust, reduced access and insurance fallout after HHS bypasses expert vaccine advisory panel.

As digital clinics race to capitalize on the GLP-1 weight loss boom, concerns grow over quality, safety and the erosion of patient-centered care.

HHS announces plan to create ‘most-favored-nation’ cost scale so U.S. is not subsidizing drug prices in other countries.

‘Wild west’ of pharmaceutical sales developed as patients clamor for GLP-1s for obesity treatment.

Novavax continues working with FDA, but case could signal a shift in broader vaccine procedures.

Moves prompt praise from opponents of high costs of medications, PBMs.

Are your patients' medications about to get more expensive?

As obesity medications gain popularity, many older Americans support coverage — but not higher premiums.

Policy center argues patients around the world benefit when Americans pay more than their fair share for research and medicines.

HELP Committee Senators press Trump’s FDA pick on the cancelled vaccine advisory meeting, mifepristone access, transparency and agency layoffs.

President Trump says it’s necessary to impose extra costs on goods from Canada, Mexico and China. What does that mean for the health care sector? Potentially, a lot.

Executive order says HHS will ‘rapidly enforce’ price disclosures by hospitals, health insurers.

UCLA research highlights the widespread use of non-evidence-based treatments during the COVID-19 pandemic, raising concerns about the role of misinformation and health care spending.

Both sides support revising laws for PBM market, but Democrats and Republicans disagree on potential Medicaid changes.

Prevention beats treatment for everyone — patients, payers and investors.

A study of the medical economics of ultraprocessed foods, diabetes and pharmaceutical revenues.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

What new treatments mean for practices and patients.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

An expert on antimicrobial resistance discusses how it involves patients in local doctors’ offices and around the world.

Study examined Amazon’s RxPass to see how it affected medication adherence and cost

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.